Income Statement EssilorLuxottica
Equities
EL
FR0000121667
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 206.70 EUR | +0.10% |
|
+0.98% | -23.42% |
| 04-21 | Danone, DMS, Vusion... stocks to watch tomorrow in Paris | |
| 04-21 | European markets bend but do not break |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 19.82B | 24.49B | 25.4B | 26.51B | 28.49B | |||||
Total Revenues | 19.82B | 24.49B | 25.4B | 26.51B | 28.49B | |||||
Cost of Goods Sold, Total | 7.71B | 9.12B | 9.56B | 9.93B | 11.47B | |||||
Gross Profit | 12.11B | 15.37B | 15.83B | 16.57B | 17.02B | |||||
Selling General & Admin Expenses, Total | 9.03B | 11.55B | 12B | 12.47B | 12.9B | |||||
Stock-Based Compensation (IS) | - | - | - | - | - | |||||
R&D Expenses | 579M | 600M | 593M | 631M | 664M | |||||
Other Operating Expenses | -5M | -6M | -21M | -5M | -22M | |||||
Other Operating Expenses, Total | 9.6B | 12.14B | 12.57B | 13.09B | 13.55B | |||||
Operating Income | 2.51B | 3.23B | 3.26B | 3.48B | 3.47B | |||||
Interest Expense, Total | -141M | -156M | -198M | -253M | -314M | |||||
Interest And Investment Income | 30M | 30M | 87M | 97M | 96M | |||||
Net Interest Expenses | -111M | -126M | -111M | -156M | -218M | |||||
Income (Loss) On Equity Invest. | 3M | 6M | -1M | 3M | - | |||||
Currency Exchange Gains (Loss) | -11M | 12M | -7M | 20M | 69M | |||||
Other Non Operating Income (Expenses) | -7M | -19M | -23M | -24M | -36M | |||||
EBT, Excl. Unusual Items | 2.38B | 3.1B | 3.12B | 3.32B | 3.29B | |||||
Restructuring Charges | -96M | -67M | -96M | -52M | -63M | |||||
Merger & Related Restructuring Charges | -65M | -11M | - | -13M | -12M | |||||
Gain (Loss) On Sale Of Investments | - | 41M | 12M | - | - | |||||
Gain (Loss) On Sale Of Assets | -2M | 9M | -2M | - | -3M | |||||
Asset Writedown | -51M | -24M | - | - | - | |||||
Legal Settlements | - | - | - | -10M | -15M | |||||
Other Unusual Items | 34M | -20M | - | 42M | - | |||||
EBT, Incl. Unusual Items | 2.2B | 3.03B | 3.04B | 3.29B | 3.2B | |||||
Income Tax Expense | 587M | 751M | 609M | 800M | 752M | |||||
Earnings From Continuing Operations | 1.61B | 2.28B | 2.43B | 2.49B | 2.44B | |||||
Net Income to Company | 1.61B | 2.28B | 2.43B | 2.49B | 2.44B | |||||
Minority Interest | -150M | -128M | -137M | -132M | -128M | |||||
Net Income - (IS) | 1.46B | 2.15B | 2.29B | 2.36B | 2.32B | |||||
Net Income to Common Incl Extra Items | 1.46B | 2.15B | 2.29B | 2.36B | 2.32B | |||||
Net Income to Common Excl. Extra Items | 1.46B | 2.15B | 2.29B | 2.36B | 2.32B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 3.33 | 4.87 | 5.11 | 5.2 | 5.04 | |||||
Basic EPS - Continuing Operations | 3.33 | 4.87 | 5.11 | 5.2 | 5.04 | |||||
Basic Weighted Average Shares Outstanding | 439M | 442M | 448M | 454M | 459M | |||||
Net EPS - Diluted | 3.28 | 4.83 | 5.08 | 5.13 | 4.98 | |||||
Diluted EPS - Continuing Operations | 3.28 | 4.83 | 5.08 | 5.13 | 4.98 | |||||
Diluted Weighted Average Shares Outstanding | 445M | 446M | 451M | 460M | 465M | |||||
Normalized Basic EPS | 3.05 | 4.1 | 4.05 | 4.29 | 4.2 | |||||
Normalized Diluted EPS | 3 | 4.06 | 4.02 | 4.23 | 4.15 | |||||
Dividend Per Share | 2.51 | 3.23 | 3.95 | 3.95 | 4 | |||||
Payout Ratio | 9.43 | 21.1 | 21.28 | 49.3 | 23.63 | |||||
American Depositary Receipts Ratio (ADR) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |||||
Supplemental Items | ||||||||||
EBITDA | 4.2B | 5.23B | 5.28B | 5.56B | 5.57B | |||||
EBITA | 3.59B | 4.53B | 4.57B | 4.78B | 4.73B | |||||
EBIT | 2.51B | 3.23B | 3.26B | 3.48B | 3.47B | |||||
EBITDAR | 4.61B | 5.78B | 5.85B | 6.14B | 6.17B | |||||
Effective Tax Rate - (Ratio) | 26.68 | 24.78 | 20.07 | 24.31 | 23.54 | |||||
Total Current Taxes | 783M | 898M | 811M | 1.01B | 900M | |||||
Total Deferred Taxes | -197M | -147M | -202M | -206M | -148M | |||||
Normalized Net Income | 1.34B | 1.81B | 1.81B | 1.95B | 1.93B | |||||
Interest on Long-Term Debt | 52M | 69M | 90M | 112M | 126M | |||||
Non-Cash Pension Expense | -20M | 6M | 11M | 11M | 17M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 1.46B | 1.79B | 1.8B | 1.82B | 1.84B | |||||
Selling and Marketing Expenses | 7.16B | 9.5B | 9.84B | 10.34B | 10.62B | |||||
General and Administrative Expenses | 1.87B | 2.05B | 2.16B | 2.13B | 2.28B | |||||
Research And Development Expense From Footnotes | 848M | 871M | 866M | 899M | 918M | |||||
Net Rental Expense, Total | 403M | 555M | 572M | 578M | 600M | |||||
Imputed Operating Lease Interest Expense | 36.5M | 54.93M | 75.94M | 94.07M | 109M | |||||
Imputed Operating Lease Depreciation | 367M | 500M | 496M | 484M | 491M | |||||
Stock-Based Comp., COGS (Total) | 2M | - | - | - | 70M | |||||
Stock-Based Comp., S&M Exp. (Total) | 1M | - | - | - | - | |||||
Stock-Based Comp., G&A Exp. (Total) | 5M | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | 202M | 206M | 220M | 214M | 285M | |||||
Total Stock-Based Compensation | 210M | 206M | 220M | 214M | 355M |
- Stock Market
- Equities
- EL Stock
- Financials EssilorLuxottica
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















